Patents by Inventor Dayeon Yu

Dayeon Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of atopic dermatitis and asthma using RNA complexes that target IL4R?, TRPA1, or F2RL1
    Patent number: 10947541
    Abstract: In certain aspects, provided herein are RNA complexes (e.g., asymmetric RNA complexes, such as asiRNAs or cell penetrating asiRNAs) that inhibit IL4R?, TRPA1, and/or F2RL1 expression and are therefore useful for treating atopic dermatitis or asthma.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: March 16, 2021
    Assignee: OliX Pharmaceuticals, Inc.
    Inventors: Dong-Ki Lee, Sun Woo Hong, Hanna Lee, Dayeon Yu, Ji Eom
  • TREATMENT OF ANGIOGENESIS-ASSOCIATED DISEASES USING RNA COMPLEXES THAT TARGET ANGPT2 AND PDGFB
    Publication number: 20200123548
    Abstract: In certain aspects, provided herein are RNA complexes (e.g., asymmetric RNA complexes, such as asiRNAs or cell penetrating asiRNAs) that inhibit ANGPT2 and/or PDGFB expression and are therefore useful for treating angiogenesis-associated diseases, such as cancer, AMD, and DME.
    Type: Application
    Filed: October 29, 2019
    Publication date: April 23, 2020
    Inventors: Dong-Ki LEE, Sun Woo HONG, Tae Yeon LEE, Sae-Lo-Oom LEE, Hanna LEE, Dayeon YU, Ji EOM
  • TREATMENT OF ATOPIC DERMATITIS AND ASTHMA USING RNA COMPLEXES THAT TARGET IL4Ra, TRPA1, OR F2RL1
    Publication number: 20200109405
    Abstract: In certain aspects, provided herein are RNA complexes (e.g., asymmetric RNA complexes, such as asiRNAs or cell penetrating asiRNAs) that inhibit IL4R?, TRPA1, and/or F2RL1 expression and are therefore useful for treating atopic dermatitis or asthma.
    Type: Application
    Filed: July 17, 2019
    Publication date: April 9, 2020
    Inventors: Dong-Ki LEE, Sun Woo HONG, Hanna LEE, Dayeon YU, Ji EOM
  • Treatment of angiogenesis-associated diseases using RNA complexes that target ANGPT2 and PDGFB
    Patent number: 10519449
    Abstract: In certain aspects, provided herein are RNA complexes (e.g., asymmetric RNA complexes, such as asiRNAs or cell penetrating asiRNAs) that inhibit ANGPT2 and/or PDGFB expression and are therefore useful for treating angiogenesis-associated diseases, such as cancer, AMD, and DME.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: December 31, 2019
    Assignee: OliX Pharmaceuticals, Inc.
    Inventors: Dong Ki Lee, Sun Woo Hong, Tae Yeon Lee, Sae-Lo-Oom Lee, Hanna Lee, Dayeon Yu, Ji Eom
  • Treatment of atopic dermatitis and asthma using RNA complexes that target IL4R?, TRPA1, or F2RL1
    Patent number: 10358648
    Abstract: In certain aspects, provided herein are RNA complexes (e.g., asymmetric RNA complexes, such as asiRNAs or cell penetrating asiRNAs) that inhibit IL4R?, TRPA1, and/or F2RL1 expression and are therefore useful for treating atopic dermatitis or asthma.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: July 23, 2019
    Assignee: OliX Pharmaceuticals, Inc.
    Inventors: Dong Ki Lee, Sun Woo Hong, Hanna Lee, Dayeon Yu, Ji Eom
  • Treatment of Angiogenesis-Associated Diseases Using RNA Complexes that Target ANGPT2 and PDGFB
    Publication number: 20170218374
    Abstract: In certain aspects, provided herein are RNA complexes (e.g., asymmetric RNA complexes, such as asiRNAs or cell penetrating asiRNAs) that inhibit ANGPT2 and/or PDGFB expression and are therefore useful for treating angiogenesis-associated diseases, such as cancer, AMD, and DME.
    Type: Application
    Filed: February 1, 2017
    Publication date: August 3, 2017
    Inventors: Dong-Ki Lee, Sun Woo Hong, Tae Yeon Lee, Sae-Lo-Oom Lee, Hanna Lee, Dayeon Yu, Ji Eom
  • TREATMENT OF ATOPIC DERMATITIS AND ASTHMA USING RNA COMPLEXES THAT TARGET IL4Ra, TRPA1, OR F2RL1
    Publication number: 20170218376
    Abstract: In certain aspects, provided herein are RNA complexes (e.g., asymmetric RNA complexes, such as asiRNAs or cell penetrating asiRNAs) that inhibit IL4R?, TRPA1, and/or F2RL1 expression and are therefore useful for treating atopic dermatitis or asthma.
    Type: Application
    Filed: February 1, 2017
    Publication date: August 3, 2017
    Inventors: Dong-Ki Lee, Sun Woo Hong, Hanna Lee, Dayeon Yu, Ji Eom